Patent US5053423A successfully refreshed from Google Patents.
US5053423A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions for photodynamic therapy
Assignee: Novelion Therapeutics Inc
•
Filing: 1990-03-22
•
Granted: 1991-10-01
•
Expires: 2010-03-22
Abstract
Abstract Porphyrin-type photosensitizers useful in photodynamic therapy can be formulated as water soluble drugs by conjugation of the photosensitizer to a hydrophilic polymer. Conjugation of the photosensitizer in varying ratios to the polymer, such as polyvinyl alcohol, provides compositions which are readily soluble and biodistribute in a fashion equal to or advantageous over that obtained when the photosensitizer is administered alone. In addition, these conjugates which further a contain target specific component provide a mechanism for homing to the desired target tissue, as well as offering a convenient approach to including both target specific component and photosensitizing drug in the same complex.
Inventors
- 👤 Daniel Liu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 04:12
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/58; A61K47/61
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
38 words
A pharmaceutical composition useful for photodynamic therapy which composition contains, as active ingredient, a conjugate of a porphyrin-type photosensitizer with a hydrophilic, water soluble, multifunctional polymeric carrier, wherein the ratio of photosensitizer to carrier is 1:1 to 500:1.
Claim 2
Dependent Claim
38 words
A pharmaceutical composition useful for photodynamic therapy which composition contains, as active ingredient, a conjugate of a porphyrin-type photosensitizer with a hydrophilic, water soluble, multifunctional polymeric carrier, wherein the ratio of photosensitizer to carrier is 1:1 to 500:1.
Claim 3
Dependent Claim
19 words
The pharmaceutical composition of claim 1 wherein said multifunctional polymeric carrier contains a multiplicity of amino or hydroxyl groups.
Claim 4
Dependent Claim
24 words
The composition of claim 2 wherein said carrier is selected from the group consisting of a polysaccharide, polyallylamine, polyvinyl alcohol, and an esterified polyacrylate.
Claim 5
Dependent Claim
12 words
The composition of claim 1 wherein the carrier is a polyvinyl alcohol.
Claim 6
Dependent Claim
74 words
The composition of claim 1 wherein the porphyrin-type photosensitizer comprises a green porphyrin of formulas 1-6 of FIG. 1 wherein each R 1 and R 2 is independently selected from the group consisting of carbalkoxy (2-6C), alkyl (1-6C) sulfonyl, aryl (6-10C) sulfonyl, cyano, and --CONR 5 CO-- wherein R 5 is aryl (6-10C) or alkyl (1-6C); and wherein each R 3 is lower alkyl (1-4C) or w-carboxalkyl (2-6C) or the esters or amides thereof.
Claim 7
Dependent Claim
38 words
The composition of claim 5 wherein the green porphyrin is of formula 3 or 5 in FIG. 1 and wherein each R 1 and R 2 is independently carbalkoxy (2-6C) and each R 3 is carbalkoxyethyl or carboxyethyl.
Claim 8
Dependent Claim
17 words
The composition of claim 1 wherein the porphyrin-type photosensitizer is a mixture of porphyrins containing dihematoporphyrin ether.
Claim 9
Dependent Claim
14 words
The composition of claim 1 wherein the ratio of photosensitizer to carrier is 10:1-75:1.
Claim 10
Dependent Claim
23 words
The composition of claim 4 wherein the PVA has a molecular weight of ˜10,000 and the ratio of photosensitizer to PVA is 75:1-10:1.
Claim 11
Dependent Claim
14 words
The composition of claim 1 wherein said conjugate further contains a target specific component.
Claim 12
Dependent Claim
18 words
The composition of claim 10 wherein the ratio of target specific component to carrier is between about 5:1-1:1.
Claim 13
Dependent Claim
18 words
The composition of claim 10 wherein said target specific component is an immunoglobulin or an immunoreactive fragment thereof.
Claim 14
Dependent Claim
14 words
The composition of claim 12 wherein said target specific component is a monoclonal antibody.
Claim 15
Dependent Claim
80 words
A method to impair the function of target cells or viruses, which method comprises contacting said cells or viruses with an effective amount of the composition of claim 1 in a manner which permits the accumulation of the conjugate in said cells or viruses, followed by irradiating said cells or viruses with an effective amount of radiation at a wavelength absorbed by the photosensitizer contained in the conjugate for a time and intensity sufficient to impair said cells or viruses.
Claim 16
Dependent Claim
11 words
The method of claim 14 wherein said cells are cancer cells.
Claim 17
Dependent Claim
11 words
The method of claim 14 wherein said target moieties are viruses.
Claim 18
Dependent Claim
15 words
The method of claim 14 wherein said target moieties are contained in a living organism.
Claim 19
Dependent Claim
80 words
A method to impair the function of target cells or viruses, which method comprises contacting said cells or viruses with an effective amount of the composition of claim 10 in a manner which permits the accumulation of the conjugate in said cells or viruses, followed by irradiating said cells or viruses with an effective amount of radiation at a wavelength absorbed by the photosensitizer contained in the conjugate for a time and intensity sufficient to impair said cells or viruses.
Claim 20
Dependent Claim
11 words
The method of claim 18 wherein said cells are cancer cells.
Claim 21
Dependent Claim
11 words
The method of claim 18 wherein said target moieties are viruses.
Claim 22
Dependent Claim
15 words
The method of claim 18 wherein said target moieties are contained in a living organism.
References Cited (Backward Citations)
US4268947A
Cited
US4500507A
Cited
US4649151A
Cited
US4512762A
Cited
US4577636A
Cited
US4727027A
Cited
US4748120A
Cited
US4485806A
Cited
US4675338A
Cited
US4753958A
Cited
US4883790A
Cited
US4920143A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-30 | 1995-04-01 | 1995-10-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-30 | 1999-04-01 | 1999-10-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-30 | 2003-04-01 | 2003-10-01 | $7700.00 | Window Closed / Lapsed |